Peptide-peptidase inhibitor conjugates and methods of using same
View Patent ↗Peptide-peptidase inhibitor conjugate molecules are disclosed. These conjugate molecules are useful as agents for the treatment and prevention of metabolic and cardiovascular diseases, disorders, and conditions. Such diseases, conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, and other diabetes-related disorders.
1. A peptide-peptidase inhibitor conjugate comprising a peptide covalently linked to a peptidase inhibitor, wherein the peptide comprises exendin-3, exendin-4, or an exendin analog comprising the sequence set forth in any one of SEQ ID NOs:65-71 and 73, wherein the peptidase inhibitor comprises an angiotensin-converting enzyme inhibitor, and wherein the peptide-peptidase inhibitor conjugate is synthesized chemically or recombinantly.
2. The conjugate of claim 1 wherein the plasma half-life of the conjugate is greater than the plasma half-life of the peptide not conjugated to the peptidase inhibitor.
3. A pharmaceutical composition comprising the conjugate of claim 1 .
4. A method for treating a metabolic disease or a cardiovascular disease in a subject in need thereof comprising administering a therapeutically effective amount of the conjugate of claim 1 .
5. A method of decreasing degradation of a peptidase-sensitive peptide in a subject comprising administering a composition comprising the peptide-peptidase inhibitor conjugate compound according to claim 1 to a subject in an amount effective to decrease degradation of a peptidase-sensitive peptide.
6. A method of increasing plasma concentration of a biologically active, peptidase-sensitive peptide in a subject comprising administering a composition comprising the peptide-peptidase inhibitor according to claim 1 to a subject in an amount effective to increase plasma half-life of a biologically active, peptidase-sensitive peptide.